These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 11342931)

  • 1. Antibody induced coagulopathy from bovine thrombin use during partial nephrectomy.
    Pavlovich CP; Battiwalla M; Rick ME; Walther MM
    J Urol; 2001 May; 165(5):1617. PubMed ID: 11342931
    [No Abstract]   [Full Text] [Related]  

  • 2. Immune-mediated coagulopathy associated with topical bovine thrombin: review of the pediatric literature.
    Rodgers GM
    J Pediatr Hematol Oncol; 2011 Mar; 33(2):86-8. PubMed ID: 21228719
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune-mediated coagulopathy: a case report.
    Naoum JJ
    Pharmacotherapy; 2009 Jul; 29(7 Pt 2):13S-7S. PubMed ID: 19558280
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bovine thrombin and the clinical consequence of antibody development.
    Cronstein BN
    J Am Coll Surg; 2008 Jan; 206(1):199; author reply 199-200. PubMed ID: 18155591
    [No Abstract]   [Full Text] [Related]  

  • 5. Thrombin products: economic impact of immune-mediated coagulopathies and practical formulary considerations.
    Voils SA
    Pharmacotherapy; 2009 Jul; 29(7 Pt 2):18S-22S. PubMed ID: 19558281
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of antibodies to topical bovine thrombin after abdominal hysterectomy. A case report.
    Adams JD; Jones S; Brost BC
    J Reprod Med; 2001 Oct; 46(10):909-12. PubMed ID: 11725736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bovine thrombin: history, use, and risk in the surgical patient.
    Diesen DL; Lawson JH
    Vascular; 2008; 16 Suppl 1():S29-36. PubMed ID: 18544303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antihuman factor V antibodies after use of relatively pure bovine thrombin.
    Lawson JH; Lynn KA; Vanmatre RM; Domzalski T; Klemp KF; Ortel TL; Niklason LE; Parker W
    Ann Thorac Surg; 2005 Mar; 79(3):1037-8. PubMed ID: 15734434
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factor V inhibitor after injection of human thrombin (tissucol) into a bleeding peptic ulcer.
    Caers J; Reekmans A; Jochmans K; Naegels S; Mana F; Urbain D; Reynaert H
    Endoscopy; 2003 Jun; 35(6):542-4. PubMed ID: 12783357
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A safety review of topical bovine thrombin-induced generation of antibodies to bovine proteins.
    Ofosu FA; Crean S; Reynolds MW
    Clin Ther; 2009 Apr; 31(4):679-91. PubMed ID: 19446142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of antibodies to human thrombin and factor V in a pediatric patient exposed to topical bovine thrombin.
    Lo CY; Jones C; Glader B; Zehnder JL
    Pediatr Blood Cancer; 2010 Dec; 55(6):1195-7. PubMed ID: 20979176
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The coagulation cascade and surgical hemostasis. Introduction.
    Voils SA
    Pharmacotherapy; 2009 Jul; 29(7 Pt 2):1S. PubMed ID: 19558277
    [No Abstract]   [Full Text] [Related]  

  • 13. Cross-reactivity of rabbit anti-bovine thrombin IgGs with human alpha-thrombin and a recombinant version of human thrombin (Recothrom).
    He Zhu ; Hoppensteadt D; Cunanan J; Fareed J
    Clin Appl Thromb Hemost; 2010 Jun; 16(3):273-80. PubMed ID: 20547555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Persistence of antibodies to the topical hemostat bovine thrombin.
    Randleman CD; Singla NK; Renkens KL; Souza S; Pribble JP; Alexander WA
    J Am Coll Surg; 2010 Dec; 211(6):798-803. PubMed ID: 20980172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune responses associated with perioperative exposure and reexposure to topical bovine thrombin do not impair hemostasis.
    Paterson CA; Pixton GC; Proskin HM; Massaro JM; Morasch M; Cronstein B; Fareed J; Ofosu FA
    Clin Appl Thromb Hemost; 2011; 17(6):620-32. PubMed ID: 21596694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase 3b, open-label, single-group immunogenicity and safety study of topical recombinant thrombin in surgical hemostasis.
    Singla NK; Ballard JL; Moneta G; Randleman CD; Renkens KL; Alexander WA
    J Am Coll Surg; 2009 Jul; 209(1):68-74. PubMed ID: 19651065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of factor V and thrombin inhibitors in children following bovine thrombin exposure during cardiac surgery: a report of three cases.
    Bomgaars L; Carberry K; Fraser C; West A; Teruya J
    Congenit Heart Dis; 2010; 5(3):303-8. PubMed ID: 20576051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Postoperative coagulopathy in a pediatric patient after exposure to bovine topical thrombin.
    Crow SS; Sullivan VV; Aysola AE; Key NS; Harker-Murray P; Foker JE; Steiner ME
    Ann Thorac Surg; 2007 Apr; 83(4):1547-9. PubMed ID: 17383385
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Achieving hemostasis in the surgical field.
    Boucher BA; Traub O
    Pharmacotherapy; 2009 Jul; 29(7 Pt 2):2S-7S. PubMed ID: 19558278
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and immunogenicity observations pooled from eight clinical trials of recombinant human thrombin.
    Ballard JL; Weaver FA; Singla NK; Chapman WC; Alexander WA
    J Am Coll Surg; 2010 Feb; 210(2):199-204. PubMed ID: 20113940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.